Pfizer comments on ORAL Sync tofacitinib data
25 April 2011 | By Pfizer Inc.
Pfizer has commented on an abstract concerning the ORAL Sync Phase 3 study of tofacitinib in patients with rheumatoid arthritis...
List view / Grid view
25 April 2011 | By Pfizer Inc.
Pfizer has commented on an abstract concerning the ORAL Sync Phase 3 study of tofacitinib in patients with rheumatoid arthritis...
20 April 2011 | By Pfizer
Shanghai Pharmaceutical Co. Ltd. and Pfizer Inc. today announced the signing of a MOU...
15 April 2011 | By Pfizer
Pfizer Inc. announced top-line results from the ORAL Scan Phase 3 study (A3921044)...
11 April 2011 | By GDS International
Every other industry is getting on the social media bandwagon. But could social media actually prove beneficial to the world of pharma?...
11 April 2011 | By Citigate Dewe Rogerson Ltd
immatics, announced that Pfizer are to support its pivotal Phase III trial (IMPRINT) with IMA901...
28 March 2011 | By De Montfort University
De Montfort University’s unique QbD course received major endorsement by senior industry leaders when it was launched last week...
17 March 2011 | By GDS International
Personalised medicine is making a comeback – but will it stick this time?...
11 March 2011 | By PharmaChemical Ireland
PharmaChemical Ireland, welcomed the news that Amgen has agreed to purchase Pfizer’s manufacturing facility in Dun Laoghaire, Co Dublin...
10 March 2011 | By Pfizer
View and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide R&D...
1 March 2011 | By Pfizer
Pfizer completed its acquisition of King through the merger of its wholly owned subsidiary, Parker Tennessee Corp...
25 February 2011 | By GlaxoSmithKline
GSK, ViiV Healthcare, & Pfizer announced the appointment of David Redfern as the new Chairman of the Board for ViiV Healthcare...
14 February 2011 | By GDS International
What are the strategies for reducing drug attrition rates in the clinic through the application of transgenic rodent models?...
14 February 2011 | By Integra Communications Ltd
A significant number of new, innovative pharmaceutical companies could emerge from the releasing of talented Pfizer scientists...
10 February 2011 | By Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announce the publication of their AVERROES study of apixaban in The New England Journal of Medicine...
16 December 2010 | By Attila A. Seyhan, Translational Immunology, Inflammation and Immunology, Pfizer Pharmaceuticals
Recent advances in RNA interference (RNAi) technology and availability of RNAi libraries in various formats and genome coverage have impacted the direction and speed of drug target discovery and validation efforts. After the introduction of RNAi inducing reaagent libraries in various formats, systematic functional genome screens have been performed to…